ZIOPHARM Oncology, Inc., a bio pharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for Ad-RTS-hIL-12 + veledimex in the treatment of patients with malignant Glioma. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response.
“Malignant glioma is an aggressive cancer with few treatment options,” said Laurence J. N. Cooper, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. “This designation supports our effort to advance Ad-RTS-IL-12, a novel immuno-oncology therapy which has demonstrated promising preclinical efficacy in brain cancer.”
View the full release here.